Biogen Inc (BIIB)
$214.68+6.30%
Spriggl Score: Moderate— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Franchise transition broadening with new acquisitions, but drug-revenue decline and rising debt limit conviction.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCL…
- Sector:
- Healthcare
- Industry:
- Drug Manufacturers - General
- Market Cap:
- $29.0B
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Biogen Inc and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free